On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. (Q46544698)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

main subject

myelodysplastic syndrome

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

François Guilhot

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Alan F List

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

E J Feldman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J Cortes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

D J DeAngelo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

B Simonsson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

S G O'Brien

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J Reiffers

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

A R Turner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

G J Roboz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J H Lipton

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

F Maloisel

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

P Colombat

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

G Martinelli

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J L Nielsen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

S Petersdorf

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J Barker

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

P Kirschmeier

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

E Frank

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

P Statkevich

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Y Zhu

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

S Loechner

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

12 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1707-1711

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18548095%20AND%20SRC:MED&resulttype=core&format=json

Myelodysplastic syndrome.

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.156